Publicaciones en colaboración con investigadoras/es de Hospital Virgen de la Arrixaca (77)

2024

  1. 2-Hydroxyethyl methacrylate (2-HEMA) sensitization, a global epidemic at its peak in Spain?

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 507-513

  2. A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight

    Contact Dermatitis, Vol. 91, Núm. 3, pp. 228-236

  3. Epidemiological, Clinical, and Allergic Profile of Psoriatic Patients. Evaluation of the Spanish Registry of Contact Dermatitis and Cutaneous Allergy (REIDAC)

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 6, pp. 539-546

  4. Four-year Epidemiological Surveillance of the Spanish Registry of Research in Contact Dermatitis and Cutaneous Allergy: Current Situation and Trends

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 4, pp. 331-340

  5. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  6. Patch test results to the Spanish baseline patch test series according to age groups: A multicentric prospective study from 2019 to 2023

    Contact Dermatitis

  7. Polysensitization in the Spanish Contact Dermatitis Registry (REIDAC): A 2019–2022 prospective study with cluster and network analysis

    Journal of the European Academy of Dermatology and Venereology

  8. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

  9. Sensitization to textile dyes in Spain: Epidemiological situation (2019–2022)

    Contact Dermatitis, Vol. 90, Núm. 5, pp. 486-494

  10. Sodium metabisulfite a current low relevant allergen in Spain

    Journal of the European Academy of Dermatology and Venereology

  11. Standard and Expanded Series Patch Testing Update by the Spanish Contact Dermatitis and Skin Allergy Research Group (GEIDAC)

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 712-721

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  3. Correction: Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection (Trials, (2021), 22, 1, (851), 10.1186/s13063-021-05777-6)

    Trials

  4. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  5. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  6. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain

    Dermatitis, Vol. 34, Núm. 4, pp. 315-322

  7. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study

    Reumatologia Clinica, Vol. 19, Núm. 6, pp. 312-318

2022

  1. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  2. Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination in Kidney Transplant Recipients

    Transplantation, Vol. 106, Núm. 7, pp. 1430-1439